IRCT20091012002582N21 IRCT 2020-05-18 Tabriz University of Medical Sciences Effect of intrapulmonary injection of processed serum derived from covid-19 patients in reduction of pulmonary complications - Effect of intratracheal Injection of Processed Autologous Serum Derived from Patients with covid-19 in oxygenation parameters and pulmonary Complications 2019-05-05 anticipated 30 Complete https://irct.ir/trial/47197 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Initially, the blocks (n=4) with different arrangements of A and B will be defined. Considering the different probable arrangement of A and B, blocks will be numbered from 1 to 6. To enroll initial 4 patients into the study, one of the arrangements will be selected using the random digit table and the patients will be assigned into the A and B groups accordingly. For the next 4 patients, the arrangement pattern will be selected again and the patients will be assigned to the groups and this cycle will be repeated to achieve our intended sample size. Unpredictability of assignment and balancing the number of patients across the two groups during or at the end of the study are main advantages of this method. Notably, the patients will be assigned into the study based on the ICU date of admission and no body will be able to assign the patients to the specific group of interest, Blinding description: The aim of double blinding is the avoidance of patients and researchers from being informed about the study intervention, so enrollment of patients in intervention and placebo groups will not be recognized. As the patients will be unconscious and under mechanical ventilation, they actually will not be aware of the group in which they are (intervention /placebo). The informed consent will be obtained from the patient's next of kin and they will thoroughly be informed about the study but they will be blind about the group in which their patient will be included. Also, the researcher who will assess the outcomes will not have any information about study enrollment and only primary investigator will know that. So, blinding will be performed for the researcher who will assess the study outcomes. As he/she will not be a member of treatment team and will be blinded to the study groups. 2 COVID-19. Intervention 1: Intervention group: After taking blood samples and centrifugation with 5000/min the plasma will be separated and incubated for 8 hours and then this plasma will be injected intratracheally for the patient. This procedure will be performed every 3 days and the maximum number of administration will be 3 times. Intervention 2: Control group:in the same volume for the patients in control group normal saline is intratracheally will be injected.This procedure will be performed every 3 days and the maximum number of administration will be 3 times. No - There is not a plan to make this available Justification or reason for not sharing IPD is Will be available if needed